Regeneron, the US pharma giant which employs 1,400 people in Limerick, has agreed to buy the immune-oncology drug Libtayo from partner Sanofi for as much as $1.1bn (€1bn), revisiting a deal that helped the French company re-enter the field of cancer research. Sanofi will get an upfront payment of $900m to transfer all rights to Libtayo to its US partner and stands to get another $200m in milestone payments if the drug reaches certain regulatory and sales targets.

Source: Irish Examiner June 03, 2022 01:15 UTC